anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peptidyl arginine deiminase 4 (PAD4) plays a pivotal role in infection and inflammatory diseases by facilitating the formation of neutrophil extracellular traps (NETs). However, the substrates of PAD4 and its exact role in inflammatory bowel disease (IBD) remain unclear. In this study, we employed single-cell RNA sequencing (scRNA-seq) and substrate citrullination mapping to decipher the role of PAD4 in intestinal inflammation associated with IBD. Our results demonstrated that PAD4 deficiency alleviated colonic inflammation and restored intestinal barrier function in a dextran sulfate sodium (DSS)-induced colitis mouse model. scRNA-seq analysis revealed significant alterations in intestinal cell populations, with reduced neutrophil numbers and changes in epithelial subsets upon PAD4 deletion. Gene expression analysis highlighted pathways related to inflammation and epithelial cell function. Furthermore, we found that neutrophil-derived extracellular vesicles (EVs) carrying PAD4 were secreted into intestinal epithelial cells (IECs). Within IECs, PAD4 citrullinates mitochondrial creatine kinase 1 (CKMT1) at the R242 site, leading to reduced CKMT1 protein stability via the autophagy pathway. This action compromises mitochondrial homeostasis, impairs intestinal barrier integrity, and induces IECs apoptosis. IEC-specific depletion of CKMT1 exacerbated intestinal inflammation and apoptosis in mice with colitis. Clinical analysis of IBD patients revealed elevated levels of PAD4, increased CKMT1 citrullination, and decreased CKMT1 expression. In summary, our findings highlight the crucial role of PAD4 in IBD, where it modulates IECs plasticity via CKMT1 citrullination, suggesting that PAD4 may be a potential therapeutic target for IBD.
Background and Objectives.Primordial dwarfism (PD) is a rare group of genetic conditions where individuals experience severe growth restriction, both in the womb and after birth. From as early as the fetal stage, those affected are significantly smaller than their peers. What makes PD distinct is its slow but steady growth pattern, resulting in proportionate dwarfism, where all parts of the body are equally shortened. Diagnosing and managing PD presents significant challenges due to its rarity and the wide range of clinical and genetic variability. The main conditions in this group include Seckel syndrome, Microcephalic Osteodysplastic Primordial Dwarfism (MOPD) types I/III, MOPD type II, Meier-Gorlin syndrome, and Silver-Russell syndrome (SRS). The first four-Seckel syndrome, MOPD types I/III, MOPD type II, and Meier-Gorlin syndrome-are associated with microcephaly, and together they are known as microcephalic PD. Given how uncommon PD is, establishing its exact incidence is difficult. It is estimated that about 4 million infants die within the first month of life, with 99% of these deaths occurring in the neonatal period. Materials and Methods. Accurately diagnosing PD requires meticulous evaluation, as it can be easily confused with other genetic disorders that also cause dwarfism. In this article, we present the case of a 10-year-old patient diagnosed with MOPD II, the most common and well-documented form of microcephalic PD. Results. Genetic analysis revealed a pathogenic variant in the PCNT (pericentrin) gene ((c.1550dup, p.Gln518Alafs*7), alongside a deletion of exons 37-41. Conclusions. This case sheds light on the clinical and genetic complexities of primordial dwarfism, underscoring the importance of timely and accurate diagnosis for effective patient care.
PURPOSE:To achieve a highly sensitive and handy measurement by bringing a conjugate between an antigen determinant-containing substance (ligand) contained in a specimen and an enzyme and a second antibody with respect to an antibody of a ligand into contact with a conjugate between an antibody of the ligand and an antibody of the enzyme in a solution. CONSTITUTION:A ligand contained in a specimen, an enzyme or a high molecular compound thereof and the second antibody of an anti-ligand antibody or the second antibody of an anti-enzyme antibody are brought into contact with said antibody conjugate or a high molecular compound thereof in a solution. Here, the temperature of the solution is appropriately about 20-45 deg. and pH about 4- 8.5 normally. It is preferable in securing a moderate change in the enzyme activity that the component element should be converted into a high molecule to a certain extent and for the purpose, the second antibody is used. After the contact therebetween, the enzyme activity is measured to calculate the quantity of the ligand in the specimen. The measurement of the enzyme activity can be done by a widely-accepted method.
Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
A medicament device sensor (Sensor) comprises a body, a front wall, a back wall, an audio sensor, and a plurality of pressure sensors. The body includes a bottom surface on which the various sensors are coupled. The front wall and the back wall provide mirror symmetry in at most one plane, thereby defining a single orientation in which the Sensor attaches to the medicament device. The front wall includes a securement clip that attaches to a ledge on the medicament device. To detect secure attachment of the Sensor to the medicament device, one pressure sensor detects pressure when the Sensor is secured to the medicament device. Another one or more pressure sensors detect depression of one or more dosing buttons confirming priming of the medicament device. The audio sensor detects an inhalation confirming dispensing of medicament. In effect, the Sensor determines a dispensing event has occurred.
The invention discloses a ligusticum wallichii foot bath solution and a preparation method thereof. The ligusticum wallichii foot bath solution mainly comprises 30-40 parts of ligusticum wallichii, 20-40 parts of hairyvein agrimonia herb, 10-20 parts of radix astragali, 20-30 parts of herba epimedii, 20-38 parts of mulberry twig and 10-20 parts of ginseng. Ligusticum wallichii has effects of tonifying kidney and liver. Hairyvein agrimonia herb has effects of invigorating the circulation of blood and dredging collaterals, and reducing fat and blood sugar. Radix astragali has effects of invigorating qi for strengthening superficies and inducing dieresis. Herba epimedii has effects of tonifying kidney and yang and warming and activating meridian. Mulberry twig has effects of dispelling wind and removing moisture. Ginseng has effects of greatly tonifying primordial qi. The ligusticum wallichii foot bath solution has effects of tonifying qi and replenishing blood, and relaxing muscles and tendons and improving collateral circulation, and obviously relieves symptoms of people with weak physique and rheumatalgia.
The present invention belongs to the field of molecular marker technology, and discloses primers, segment and method for identifying the sex of air potato plant. The segment has the nucleotide sequence as shown in SEQ ID No. 1; and the primers have the nucleotide sequences as shown in SEQ ID No. 2 and SEQ ID No. 3. Using the primers in PCR reaction can obtain amplified segment of 677 bp length from male air potato plant and no any amplified product can be obtained from female air potato plant. Therefore, the primers are male air potato plant specific and may be used in identifying the sex of air potato plant.
A medication injection information monitoring structure (1) as well as a system and a medication injector thereof. The monitoring structure comprises a sleeve barrel (11) and a rotary sleeve (13). The sleeve barrel (11) has an accommodating cavity (112) on the upper end thereof. The accommodating cavity (112) is provided with a rotary encoder (15) for converting rotation information into medication injection dosage information, a control circuit board (14) and a wireless transmission structure (17). The rotary encoder (15) is fixedly connected to the rotary sleeve (13), and the rotary encoder (15) and the wireless transmission structure (17) are electrically connected to the control circuit board (14). The medication injection information monitoring structure (1) employs a direct combination of the rotary sleeve (11) and the rotary encoder (15), conversion between rotation information and medication injection dosage information is realized through rotation of the rotary sleeve (11), and a user manually rotates the rotary sleeve (11) until accurate medication injection dosage information is obtained. The monitoring structure enables accurate medication injection dosage information to be used, is convenient to use, assemble and dissemble, and does not require any special injection pen for use therewith.
This is a single-center, randomized (the study drug is assigned by chance), placebo-controlled (study in which the experimental treatment or procedure is compared to a pretend treatment with no drug in it to test if the drug has a real effect), and double-blind (neither physician nor participant knows the treatment that the participant receives) study. The study comprises a Screening Period (up to 4 weeks), a Vaccination Period (participants will be vaccinated on Days 1 and 29), and a Follow-up Period (up to 48 weeks). All eligible participants will be randomly assigned to 1 of the 2 sequential cohorts (low dose cohort and high dose cohort). Participants in low dose cohort will receive 1 of the following treatments: low dose (50 microgram \[mcg\]) gp140 drug product (DP), low dose gp140 DP with adjuvant (aluminum phosphate), placebo matched to low dose DP; and participants in high dose cohort will receive 1 of the following treatments: high dose (250 mcg) gp140 DP, high dose gp140 DP with adjuvant, and placebo matched to high dose DP. There will be an interim safety review of safety/tolerability from low-dose cohort before the high-dose cohort receives study treatment. Total study duration will be 56 weeks per participant. Participants' safety will be monitored throughout the study.
All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m\^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
<P>PROBLEM TO BE SOLVED: To provide powder for coating capable of readily carrying out coating in production of a dry coating preparation and to provide a method for producing the powder for coating and to provide a coating preparation capable of readily carrying out elution control of medicines.  <P>SOLUTION: The present invention provides powder for coating obtained by mixing a coating base suspension (e.g. acrylic coating base agent or EA/MMA/HEMA copolymer) with an electrolyte (e.g. NaCl) and collecting the aggregate and a coating preparation obtained by carrying out coating (e.g. coating using an ellipse type mixer) with the powder for coating.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Chronic rhinosinusitis is a common manifestation of CF that is associated with impaired quality of life and can be difficult to treat. CFTR modulator therapy has resulted in significant improvements in lower respiratory and nutritional outcomes for people with CF however their impact on chronic rhinosinusitis has received less attention. We review the literature in relation to chronic rhinosinusitis in CF and examine the impact of CFTR modulator therapy on symptoms, imaging, endoscopic appearances, and olfactory outcomes in the treatment of chronic rhinosinusitis. While an overall improvement in symptoms, imaging and endoscopic appearances is seen in response to treatment, limited impact is documented on olfaction. Outcome measures employed were heterogenous, limiting comparison of findings. There is a need for well powered prospective real-world studies with standardised outcome measures.
Patients with certain anatomic or medical conditions have a greater risk of serious complications following carotid endarterectomy (a surgical procedure that removes blockages in the carotid artery). Recently, these patients have been treated effectively with the implantation of a carotid stent (a metallic mesh tube). When implanting the carotid stent, physicians use devices called embolic protection devices to prevent particles from the blockage from flowing up to the brain. The TriActiv® ProGuard™ System is an embolic protection device that uses a small balloon to temporarily stop blood flow within the diseased carotid artery while the stent is implanted. Then, the TriActiv® ProGuard™ System removes any particles that may have been released from the blockage during stent implantation before blood flow is restored. This study will evaluate the safety and efficacy of the TriActiv® ProGuard™ System during carotid stent placement in patients who are considered to be at a high risk for complications from surgical endarterectomy.
Systems and methods for arranging an intraoral scanning at a selected location. A user can request an appointment at a selected intraoral scanning site from a plurality of intraoral scanning sites. In requesting the appointment at the intraoral scanning site, the user can provide various information for reserving the appointment. The user can make the request online (e.g., via an internet scheduling website associated with the intraoral scanning site). The request can also include a selected time for the appointment. The schedule for the selected intraoral scanning site can be analyzed to determine that the selected time for the appointment is available. When the appointment is scheduled for the user, one or more automatically generated messages can be communicated to the customer.
BACKGROUND: Health-related quality of life (HRQoL), which can be influenced by various aspects, especially socioeconomic status and lifestyle, has been identified as an important predictor of the prognosis of older adults. Dietary habit, a major part of lifestyle, can affect the nutritional status, which is closely correlated with the development of geriatric syndromes in the elderly.
AIMS: The aim of the study was to examine the association of HRQoL, socioeconomic status, and lifestyle with the risk and severity of sarcopenia, a geriatric syndrome characterized by progressive loss of skeletal muscle mass, strength and function.
METHODS: A cross-sectional retrospective study with 2877 participants aged ≥65 years was performed. HRQoL was assessed using EuroQoL Five Dimensions questionnaire. Socioeconomic status was assessed by the educational attainment, occupation, and household income. Lifestyle was assessed using 12 items closely related to Chinese living habits. The information of daily dietary habits including tea, alcohol, type of diet, and volume of drinking water were collected. The associations of HRQoL, socioeconomic status, and lifestyle with the risk of sarcopenia were examined by multivariate regression logistical analysis. The potential causal role of age, body mass index, and waist circumference in the effect of HRQoL on sarcopenia risk was analyzed by causal mediation analysis.
RESULTS: High HRQoL [adjusted odds ratio (OR) =0.85, 95% confidence interval (CI) =0.69-0.95, P=0.034] and household income levels (adjusted OR =0.74, 95% CI =0.57-0.95, P=0.019) were inversely associated with the risk of sarcopenia. Meanwhile, more consumption of spicy food (adjusted OR =1.34, 95% CI =1.09-1.81, P =0.037) and occasionally drinking (adjusted OR =1.46, 95% CI =1.07-2.00, P =0.016, as compared to those never drinking) were associated with higher risk of sarcopenia, while skipping breakfast occasionally (adjusted OR =0.37, 95% CI =0.21-0.64, P <0.001, as compared to those eating breakfast every day) and less consumption of salt (adjusted OR =0.71, 95% CI =0.52-0.96, P =0.026, as compared to those consuming high amount of salt) were associated with lower risk of sarcopenia. Further causal mediation analysis aimed to explore how much age, body mass index, and waist circumference might explain the effect of HRQoL on the risk of sarcopenia showed that the estimated proportion that mediated the effect of HRQoL on the risk of sarcopenia by age was 28.0%.
CONCLUSIONS: In summary, our findings demonstrate that low levels of HRQoL and household income, more intake of salt and spicy food, and occasional intake of alcohol are correlated with higher risk of sarcopenia, while skipping breakfast occasionally is associated with lower risk of sarcopenia in a Chinese population of older adults.
PROBLEM TO BE SOLVED: To obtain a composition for the oral cavity useful for preventing tooth decay, tartar and a foul breath, by formulating an abrasive material with a specific ratio of anethole and a polyhydric alcohol. SOLUTION: A pharmacologically acceptable zinc compound (e.g. zinc chloride, zinc citrate, zinc acetate or the like) is formulated with (B) preferably 0.01-1 wt.% of anethole, (C) a polyhydric alcohol (preferably sorbitol, xylitol, glycerol, a polyethylene glycol, maltitol, paratinose or the like) and preferably (D) 50-10,000 ppm calculated as fluorine of a fluoride (e.g. sodium fluoride, potassium fluoride or the like) to give the objective composition. The formulating ratio of the component B to the component C is 1:10 to 1:1,000 by weight. The composition can be in a dosage form such as a toothpaste, tooth powder, etc., and mixed with an abrasive material (e.g. silicic anhydride or the like) and a foaming agent (e.g. an anionic surfactant or the like), a preservative, etc.
The invention discloses an oral traditional Chinese medicine composition for curing psoriasis. The formula of the composition comprises the following components: arctium fruit, goosegrass herb, dodartia orientalis, patience dock root, buffalo horn, spina gleditsiae, garter snake, pangolin, wild chrysanthemum flower, smilax glabra, rhizoma sparganic with vinegar, stir-baked alisma orientalis with salt solution, plantain seed, and scorch-fried rice sprout. The "Wuniu Cishe Pill" provided by the invention has powerful and specific drug efficacy and strong specificity, overcomes the shortages existing in the other conventional drugs for curing psoriasis, has a magnificent effect by only using a small amount of composition, and has the advantages of quick curative effect and no relapse. Psoriasis is usually caused by defect of ying blood, internal blood heat, transformation of heat into dryness, generation of internal wind, and malnutrition of skin. A person usually gets the psoriasis because the person may have internal heat, then he/she gets cold from outside, the heat and cold are obstructed on the skin and cannot be discharged from the human body, and thus the disease is triggered. The medicines mentioned above cooperates with each other to have a synergic effect and have the functions of activating blood, removing toxicity and dampness, relieving itching, dredging collaterals, and adjusting organism immunity.
Cervical cancer, along with other sexual and reproductive health and rights (SRHR) conditions, poses a significant burden in the Kingdom of Saudi Arabia (KSA). Despite the availability of effective preventive methods such as vaccinations, particularly against the Human Papillomavirus (HPV), awareness about such preventive methods and HPV vaccination remains alarmingly low in the KSA, even with governmental effort and support. While many women are aware of the risks, the uptake of the HPV vaccine remains below 10% (7.6%) at the country level. This highlights the urgent need for Knowledge, Attitude, and Practice (KAP) at the community level to raise awareness, dispel misconceptions, and empower women to embrace vaccinations. Additionally, there is a need to revitalize the cancer registry system to better track and monitor cervical cancer cases. This short communication aims to map these barriers while identifying opportunities for impactful research. Drawing from the scientific literature, government reports, and expert insights, we highlight the challenges surrounding the tackling of HPV. By exploring diverse sources of knowledge, this paper not only highlights current obstacles but also proposes actionable solutions for future interventions.
BACKGROUND: A single administration of the opioid receptor antagonist methocinnamox (MCAM) antagonizes the antinociceptive effects of µ-opioid receptor agonists for 2 weeks or longer. Such a long duration of antagonism could necessitate the use of nonopioid drugs for treating pain in patients receiving MCAM for opioid use disorder (OUD).
METHODS: The antinociceptive effects of fentanyl and nonopioid drugs were assessed in 24 male Sprague Dawley rats using a complete Freund's adjuvant (CFA) model of inflammatory pain. Twelve rats received 10mg/kg MCAM and 12 received vehicle; half (n=6) of the animals from each treatment group were treated (intraplantar) with CFA or saline. Hypersensitivity to mechanical stimulation was measured using a von Frey anesthesiometer. Fentanyl (0.01-0.1mg/kg), ketamine (17.8-56mg/kg), gabapentin (32-100mg/kg), meloxicam (3.2-10mg/kg), and ∆9-tetrahydrocannabinol (THC, 1-10mg/kg) were administered intraperitoneally and tested every 3 days in a pseudorandom order. Next, the same drugs were studied for effects on motor performance using a rotarod apparatus.
RESULTS: CFA-induced hypersensitivity was attenuated by fentanyl in vehicle- but not MCAM-treated rats. THC, ketamine, and gabapentin attenuated (up to 82, 66, and 46 %, respectively) CFA-evoked mechanical hypersensitivity in both MCAM- and vehicle-treated rats. Meloxicam failed to alter CFA-evoked mechanical hypersensitivity in either group. Fentanyl, THC, gabapentin, and meloxicam did not affect motor performance in either group whereas ketamine impaired motor performance in both groups (up to 71 % reduction in latency to fall).
CONCLUSIONS: These data suggest that ketamine, gabapentin, and THC could be effective for treating inflammatory pain under conditions of long term µ-opioid receptor antagonism.
Before applying the subcutaneous injection, cold application pack was applied on the injection site for five minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
BACKGROUND: Herpesviruses are common animal and human pathogens that cause severe health problems in children, immunocompromised patients, and infected animals with a host range from fish to mammals. Anthocyanin-containing plant extracts have been described as potent antivirals, which might cause fewer harmful side effects than direct-acting antivirals. Here, we report that an extract of Aristotelia chilensis (Molina) Stuntz (Elaeocarpaceae) (MBE) with a high content of the anthocyanin delphinidin suppresses lytic replication of equine, murine and human herpesviruses of replication in vitro.
METHODS: We treated cultured cells with MBE and purified individual anthocyanins present in the extract to determine the most active compound at different concentrations. We subsequently infected the cultures with human herpesviruses 1 (HSV-1) or 8 (HHV-8), murine cytomegalovirus (CMV), or equine herpesviruses 1 (EHV-1) and determined the number of infected cells and viral infectivity.
RESULTS: MBE inhibited the HSV-1, murine CMV, and EHV-1 by up to 2 orders of magnitude. In the presence of the stabilizing randomly methylated-beta-cyclodextrin, the inhibitory concentration could be lowered significantly. We identified delphinidin as an active antiviral compound and showed that the non-glycosylated delphinidin solved and stabilized with sulfobutylether-beta-cyclodextrin allowed usage of approximately 50 times lower concentrations.
CONCLUSION: Glycosylated delphinidin derivatives were identified as active antiviral compounds of MBE. This suggests that plant extracts rich in delphinidin-anthocyanins have potent antiviral properties that could be used in treatment and prevention.